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Abstract: 
Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of dementia 
diagnosis and affects nearly 50 million people worldwide. Two classes of medications are FDA approved for the 
treatment of Alzheimer's disease (AD), acetylcholinesterase inhibitors and an NMDA receptor antagonist. Aims and 
objectives: The basic aim of the study is to analyze the medication and pharmacology of Alzheimer’s disease 
commonly used in Pakistan. Methodology of the study: This study was conducted at Services institute of medical 
sciences, Lahore during 2017. We collect the data from doctors and patients both because we want to find the 
therapeutics of AD in local population of Pakistan. Results: To provide early and accurate diagnosis of AD, 
extensive efforts have been made into developing sophisticated methods to assess pathology in the living human 
brain. However, to date, no test or combination of tests that could accurately diagnose AD is available for broad 
clinical use outside of AD research centers. Conclusion: It is concluded that there are no clear and perfect 
medication for AD. The current diseased approach for AD consists of optimizing modifiable risk factors to reduce 
and delay symptom onset as well as symptomatic treatment after disease onset.  
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common form 
of dementia accounting for 60–80% of dementia 
diagnosis and affects nearly 50 million people 
worldwide. Two classes of medications are FDA 
approved for the treatment of Alzheimer's disease 
(AD), acetylcholinesterase inhibitors (AChEI: 
donepezil, rivastigmine, galantamine, tacrine) and an 
NMDA receptor antagonist. Extant research has 
shown that race and ethnicity is a factor in the 
reported use of AD medications [1]. However, these 
have generally been drawn from data encompassing 
either a single center or geographically limited 
centers so that national trends and regional variability 
have been hard to discern. Since minority populations 
participate to a small degree in AD research, larger 
samples are necessary to determine if there is 
differential usage by these groups. The worldwide 
number of affected individuals is expected to reach 
66 million by 2030, and 131 million by 2050 as the 
number of older adult’s increases [1]. One in 10 
people over age 65 and every third person over age 
85 in the US has a diagnosis of AD. The global 
financial toll of dementia was estimated to be 818 
billion US dollars in 2015, an increase of 35% since 
2010 and this cost is expected to further rise together 
with the prevalence of AD. The majority of the costs 
are related to family and social care of patients, rather 
than medical care. About 5% of all AD patients show 
cognitive symptoms before age 65 and are classified 
as early onset Alzheimer’s disease (EOAD). Patients 
showing clinical symptoms after age 65 are classified 
as having late onset Alzheimer’s disease (LOAD) [2]. 
Here, we provide a summary of the clinical, 
neuropathological, fluid, and imaging biomarkers of 
AD along with a more comprehensive review of 
genetic findings in both Mendelian and sporadic 
forms of AD3. We discuss how genetic analysis as 
applied in Mendelian randomization (MR) may be 
helpful in validating causality of modifiable risk 
factors that could advance preventive measures. 
Moreover, genetic data may be useful to facilitate 
precision medicine. The goal of precision medicine is 
to integrate clinical, genetic, and life style data to 
enable clinicians to efficiently and accurately predict 
the most appropriate course of action for a patient. 
We emphasize the ways genetics may facilitate 
precision medicine in AD: (1) identifying at risk 
individuals through risk prediction, (2) improving 
diagnostic precision, and (3) expediting the discovery 
of targetable disease mechanisms for drug 
development4. Due to the large number of published 
articles in biomedical research of AD, we refer to 
more recent comprehensive reviews written by 
domain experts and supplement these with other 
findings [5].  
 
Figure 01: Significant pathways between AD and T2D 
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Aims and objectives 
The basic aim of the study is to analyze the 
medication and pharmacology of Alzheimer’s disease 
commonly used in Pakistan. 
 
METHODOLOGY OF THE STUDY: 
This study was conducted at Services institute of 
medical sciences, Lahore during 2017. We collect the 
data from doctors and patients both because we want 
to find the therapeutics of AD in local population of 
Pakistan.  
Data collection 
We conduct the interviews and questionnaire for 
analysis. We included publications of the Mendelian 
AD genes as well as publications that were referred 
and curated by the National Human Genome 
Research Institute-European Bioinformatics Institute 
(NHGRI-EBI) Catalog of published genome-wide 
association studies (GWAS Catalog). In addition, we 
included high-quality association studies reporting 
rare variants that meet the “analytically rigorous” 
criteria for GWAS or are otherwise statistically 
thorough. 
Statistical analysis 
All P values presented in the results are two-sided, 
and all analyses were performed by using SAS 
software. 
RESULTS: 
To provide early and accurate diagnosis of AD, 
extensive efforts have been made into developing 
sophisticated methods to assess pathology in the 
living human brain. However, to date, no test or 
combination of tests that could accurately diagnose 
AD is available for broad clinical use outside of AD 
research centers6. CSF levels of Aβ42, tau, and 
hyperphosphorylated tau as markers for amyloid, 
neuronal injury, and tangles, respectively, have been 
the main fluid biomarkers used in AD research. In 
CSF of AD patients, a decreased level of Aβ42 has 
been consistently found. Interestingly, a reduction of 
CSF Aβ42 had been shown to correlate with brain 
atrophy in non-demented elderly indicating a 
potential preclinical stage7.  
Drugs analysis 
We collect the data and form a precise table 
regarding medications which are used for the 
therapeutic approach and medication of AD. (Table 
01). 
Table 01: Drugs used for AD 
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DISCUSSION: 
Generally speaking, it is challenging and time-
consuming to isolate, identify, and screen the 
bioactive components in natural medicines. In 
addition, the components may be metabolized to 
phase I and II derivatives following absorption. 
Therefore, the bioavailability and access of 
metabolites or natural components to brain tissues are 
absolutely critical factors in predicting the potential 
for those compounds as CNS drugs [6]. A large 
number of epidemiological, preclinical and 
pathophysiology studies indicate that AD and T2DM 
share cellular and molecular mechanism [6]. The 
classical approaches in measuring comorbidity that 
are based on clinical readouts, patient data, and 
electronic health records cannot reason over the 
dysfunctional molecular activity or the impaired 
biological pathway involved in the diseased state [7]. 
On the contrary, deciphering comorbidity at a 
mechanistic level could well explain the outcomes of 
clinical readouts and patient examinations 
establishing a link between proteomic/genomic and 
phenotypic aspects of diseases. However, in this 
study we do not attempt to cover this proposal. Since 
there are no established studies aimed at explaining 
comorbidity based on shared mechanisms, we believe 
that understanding the co-morbid mechanisms 
between complex diseases can be dealt with systems 
biology approaches like integrative modeling [8]. 
 
A role of innate immunity and inflammation in AD 
etiology is independently supported by a large body 
of functional evidence. Among the risk genes from 
the immune pathways, TREM2 stands out with its 
high effect-size of AD risk. TREM2 stands for 
triggering receptor expressed on myeloid cells 2, a 
single-transmembrane protein expressed by 
monocytic myeloid cells. Both ApoE and Clusterin 
(encoded by CLU) are extracellular chaperons that 
prevent protein aggregation8. In addition, both bind to 
the microglial receptor TREM2 and thus may 
promote uptake of Aβ by microglia. Studies on 
animal and human brains indicated that the TREM2 
risk variant p.R47H impairs TREM2 detection of 
lipid ligands leading to microglia dysfunction. 
Observational studies have suggested that diabetes, 
mid-life obesity, mid-life hypertension, high 
cholesterol, and smoking are modifiable risk factors 
for AD [9]. In terms of modifiable protective factors, 
education has been robustly shown to reduce AD 
risk. However, for many modifiable factors, no 
consistent pattern was found across studies. A recent 
comprehensive meta-analysis of 93 modifiable risk 
factors was conducted from 323 retrospective 
case/control and prospective cohort studies, which 
were selected after a systematic review of 16,906 
publications. This study analyzed associations 
between AD risk and medical, dietary and 
occupational exposures as well as serum 
biochemistry, preexisting diseases, lifestyle, and 
psychological factors [10].  
CONCLUSION: 
It is concluded that there are no clear and perfect 
medication for AD. The current diseased approach 
for AD consists of optimizing modifiable risk factors 
to reduce and delay symptom onset as well as 
symptomatic treatment after disease onset.  
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